Radiopharm Theranostics: 24M options expire Sept. 30

After the options ceased, the issued-capital table lists 4,710,882,790 RAD ordinary shares and 363,179,525 unquoted RADAN options.

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd reported that 24,000,000 RADAN options expired without exercise or conversion on September 30, 2026; the company stated it was not paying consideration for the cessation. Director Riccardo Canevari separately reported disposal of 24,000,000 unlisted options expiring September 30, 2026, with an exercise price of $0.06. His direct option holdings after the change were 163,301,188, and his reported share interests were 23,918,875 direct and 2,650,000 indirect.

Filing Explained

After 24,000,000 RADAN options expired without exercise or conversion on September 30, 2026, the company reported 363,179,525 unquoted RADAN options still on issue; the expiry reduced this option class but did not eliminate it.

Key Figures

RADAN options ceased: 24,000,000 options Director's unlisted options disposed: 24,000,000 options Exercise price: $0.06 +3 more

6 metrics

RADAN options ceased 24,000,000 options Expired without exercise or conversion on September 30, 2026

Director's unlisted options disposed 24,000,000 options Riccardo Canevari; options expiring September 30, 2026

Exercise price $0.06 Riccardo Canevari's unlisted options

Director's direct options after change 163,301,188 options Riccardo Canevari

RADAN unquoted options on issue 363,179,525 options Following the cessation

RAD ordinary shares on issue 4,710,882,790 shares Following the cessation

Key Terms

Unlisted Options, issued capital, convertible security

3 terms

Unlisted Options financial

"24,000,000 Unlisted Options, EXP 30 Sept 2026, EX $0.06"

A contract that gives a specific person the right to buy or sell shares but is not traded on a public exchange; these are issued privately or over the counter, including many employee stock options or bespoke dealer agreements. They matter to investors because they are harder to value and trade, carry higher counterparty and transparency risk, and can create unexpected share dilution or contingent obligations for a company — like a custom coupon that only a few people can use instead of a store-wide voucher.

issued capital financial

"information about our issued capital"

convertible security financial

"Expiry of option or other convertible security without exercise or conversion"

A convertible security is an investment that starts as one form—typically a bond or preferred share—that the holder can swap for common stock at a set price or under certain conditions. Investors care because it combines steady income or downside protection with the upside of stock ownership: like a ticket that guarantees a seat and also lets you trade up to a VIP pass if the company performs well, affecting dilution and potential returns.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did 24,000,000 RADX RADAN options cease?

The 24,000,000 RADAN options expired without exercise or conversion on September 30, 2026. Radiopharm stated it was not paying consideration for their cessation.

How many options did RADX director Riccardo Canevari hold after the change?

Riccardo Canevari reported 163,301,188 direct options after the change. His reported share interests were 23,918,875 direct and 2,650,000 indirect.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 08:00 AM Accepted by SEC EDGAR 10/01/2026 - 07:59 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on October 1, 2026 titled:

“Change of Director’s Interest Notice (RC)”

“Notification of cessation of securities – RAD”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.

1

EXHIBITS

Exhibit Number		Description
99.1		Change of Director’s Interest Notice (RC)
99.2		Notification of cessation of securities - RAD

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 1, 2026	By:	/s/ Amritha Sushil
		Amritha Sushil
		Company Secretary

3

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.  Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		N/A
Date of change		30 September 2026

No. of securities held prior to change				Shares		Options
		Direct		23,918,875		187,301,188
		Indirect		2,650,000		-
		Total		26,568,875		187,301,188

Class		Unlisted Options
Number acquired		Nil
Number disposed		24,000,000 Unlisted Options, EXP 30 Sept 2026, EX $0.06
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		Nil

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change				Shares		Options
		Direct		23,918,875		163,301,188
		Indirect		2,650,000		-
		Total		26,568,875		163,301,188

Nature of change   Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Expiry of Unlisted Options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract		N/A
Nature of interest		N/A
Name of registered holder (if issued securities)		N/A
Date of change		N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed		N/A
Interest acquired		N/A
Interest disposed		N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation		N/A
Interest after change		N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?		No
If so, was prior written clearance provided to allow the trade to proceed during this period?		N/A
If prior written clearance was provided, on what date was this provided?		N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Exhibit 99.2

  Appendix 3H - Notification of cessation of securities

Announcement Summary

Entity name

RADIOPHARM THERANOSTICS LIMITED

Announcement Type

New announcement

Date of this announcement

Thursday October 01, 2026

Details of +securities that have ceased

ASX +security code		Security description		Number of +securities that have ceased		The +securities have ceased due to		Date of cessation
RADAN		OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES		24,000,000		Expiry of option or other convertible security without exercise or conversion		30/09/2026

Refer to next page for full details of the announcement

Appendix 3H - Notification of cessation of securities 1 / 4

  Appendix 3H - Notification of cessation of securities

Part 1 - Announcement Details

1.1 Name of +Entity

RADIOPHARM THERANOSTICS LIMITED

We (the entity named above) provide the following information about our issued capital.

	1.2 Registered Number Type		Registration Number
	ACN		647877889

1.3 ASX issuer code

RAD

1.4 The announcement is

New announcement.

1.5 Date of this announcement

1/10/2026

Appendix 3H - Notification of cessation of securities 2 / 4

  Appendix 3H - Notification of cessation of securities

Part 2 - Details of +equity securities or +debt securities that have ceased

ASX +Security Code and Description

RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Unquoted +equity securities that have ceased

Number of securities that have ceased

24,000,000

Reason for cessation

Expiry of option or other convertible security without exercise or conversion

	Date of cessation		Is the entity paying any consideration for the cessation?
	30/9/2026		No

Any other information the entity wishes to notify to ASX about the cessation?

Appendix 3H - Notification of cessation of securities 3 / 4

  Appendix 3H - Notification of cessation of securities

Part 3 - Issued capital following changes

Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)

ASX +security code and description		Total number of +securities on issue
RADO : OPTION EXPIRING 30-NOV-2026			79,352,040
RAD : ORDINARY FULLY PAID			4,710,882,790
RADOC : OPTION EXPIRING 31-JUL-2029			982,172,830
RADOB : OPTION EXPIRING 31-OCT-2027			1,179,266,658

3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)

ASX +security code and description		Total number of +securities on issue
RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60			1,666,500
RADAAB : WARRANT EXPIRING 31-JUL-2029 EX USD3.79			1,281,646
RADAAC : WARRANT EXPIRING 31-JUL-2029 EX USD3.95			64,082
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES			363,179,525
RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17			12,425,675
RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED			8,666,678
RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60			5,066,672
RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60			740,000
RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09			8,955,224

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.

Appendix 3H - Notification of cessation of securities 4 / 4

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 CHANGE OF DIRECTOR'S INTEREST NOTICE (RC) 23.0 KB
• EX-99.2 NOTIFICATION OF CESSATION OF SECURITIES - RAD 28.4 KB